SCHEMBL23239920

SCHEMBL23239920

Cc1cc(Cl)c(C)c(N(C)C)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ GAA P10253 2/20 0.33
▸ APAF1 O14727 1/20 0.32
▸ TDP2 O95551 1/20 0.32
▸ NSD2 O96028 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ THRB P10828 1/20 0.32
▸ RECQL P46063 1/20 0.32
▸ GALK1 P51570 1/20 0.32
▸ BLM P54132 1/20 0.32
▸ CASP6 P55212 1/20 0.32
▸ SAE1 Q9UBE0 1/20 0.32
▸ UBA2 Q9UBT2 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13488581 0.82 ACHE (0.36) KMT2AMEN1GAAMAPTKDM4E
SCHEMBL26281350 0.77 KMT2A (0.38) KMT2AMEN1GAAAPAF1TDP2
SCHEMBL1004002 0.76 ACHE (0.40) KMT2AMEN1MAPTNPC1LMNA
SCHEMBL7699037 0.75 RAPGEF4 (0.36) GAAMAPTLMNACYP1A2SMN1; SMN2
SCHEMBL26281346 0.72 KMT2A (0.41) KMT2AMEN1GAAAPAF1TDP2
SCHEMBL13178785 0.71 CYP1A2 (0.42) KMT2AMEN1GAAAPAF1TDP2
SCHEMBL12483803 0.71 KMT2A (0.42) KMT2AMEN1GAANPC1LMNA
SCHEMBL23214050 0.71 TTR (0.48) KMT2AMEN1LMNAKDM4EALDH1A1
SCHEMBL11429956 0.71 ALDH1A1 (0.38) KMT2AMEN1L3MBTL1SMN1; SMN2KDM4E
SCHEMBL1755250 0.69 RAPGEF4 (0.41) KMT2AMAPTL3MBTL1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2024-07-04 — — US disclosed
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2024-07-04 — — US disclosed
WO-2021069705-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS (CH) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS UPF1, NSUN2, RTF2 KMT2A 3292/4885MEN1 1094/4885GAA 1519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback